RecruitingNot ApplicableNCT05842603
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Sponsor
Massachusetts General Hospital
Enrollment
30 participants
Start Date
Mar 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of this study is to see if patients with myeloproliferative disorders are able to successfully complete the Cardiac Lifestyle Program(CLP). The goal of the CLP is to teach patients how to become more active and eat healthier foods. The name of the intervention used in this research study is: Cardiac Lifestyle Program (a 12-week, tailored nutrition and physical activity program)
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- ≥18 years of age
- Diagnosed with an MPN by WHO 2016 criteria,22 including essential thrombocythemia (ET), polycythemia vera (PV), prefibrotic myelofibrosis (pre-MF), myelofibrosis (MF), and MPN not otherwise specified (NOS). Within MF patients, only patients who are low or intermediate-1 risk by the Dynamic International Prognostic Scoring System (DIPSS) are eligible.23 All risk groups are eligible for the remaining MPN subtypes.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Must have at least one cardiovascular risk factor including: Body mass index (BMI) \>25 kg/m2, hypertension, hyperlipidemia, diabetes mellitus or pre-diabetes or metabolic syndrome, or any prior history of cardiovascular disease, transient ischemic attack, stroke, or peripheral vascular disease. Patients not meeting any cardiovascular risk criteria must receive prior approval from the PI to participate in this study.
Exclusion Criteria3
- \-- MF patients with intermediate-2 or high-risk disease by DIPSS
- ECOG performance status \>2.
- Any injury or medical condition that would prohibit being able to safely perform exercise, as determined by the treating physician.
Interventions
BEHAVIORALCardiac Lifestyle Program
12-week, tailored nutrition and physical activity program comprised of virtual and in-person classes.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05842603
Related Trials
CIML NK Cells With Venetoclax for AML
NCT061528092 locations
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
NCT068904941 location
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
NCT068562261 location
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
NCT052379863 locations
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
NCT074054241 location